Insiders · AQST

John Cochran

Director at Aquestive Therapeutics, Inc. (AQST)

John Cochran has filed 7 insider reports with the SEC since March 2021, as director at Aquestive Therapeutics, Inc. (AQST). The latest filing, on June 12, 2026, reports grant or award at Aquestive Therapeutics, Inc. (AQST).

Filings
7
Companies
1
Bought on market
None
Sold on market
None

Companies where John Cochran is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Aquestive Therapeutics, Inc. logo
AQST
Aquestive Therapeutics, Inc.
Director99,486$3.46Jun 12, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare John Cochran with

Other insiders at the same companies

Questions about John Cochran

What is John Cochran's role at Aquestive Therapeutics, Inc.?
John Cochran reports to the SEC as director at Aquestive Therapeutics, Inc. (AQST), according to the latest filing on June 12, 2026.
How many shares does John Cochran own?
After the latest filing that states it, John Cochran directly owned 99,486 shares of Aquestive Therapeutics, Inc. (AQST). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has John Cochran bought or sold stock recently?
No open-market purchases or sales by John Cochran are on file. The filings report grant or award and other acquisition or disposition.
How do I get alerts when John Cochran files?
Follow John Cochran on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by John Cochran (SEC CIK 0001406773). Totals count each trade once, skipping amendments whose original is on file, from Mar 17, 2021 on. View on SEC EDGAR · Get this as JSON